학술논문
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig® ) in the treatment of patients with primary immunodeficiencies
Document Type
Article
Author
Source
In: Clinical and Experimental Immunology . (Clinical and Experimental Immunology, November 2022, 210(2):91-103)
Subject
Language
English
ISSN
13652249
00099104
00099104